25 HNSCC and 25 SGC patients were enrolled to the study. The most common adverse events were renal insufficiency, fatigue and nausea. There were 3 deaths on study.
Efficacy in SGC: Partial response in 16% of patients and disease stabilization in 56% of patients. In the HNSCC group, median overall survival was 12.6 months and median time until disease progression was 4.5 months. In SGC, the median overall survival was 14.0 months, and median time until disease progression was 6.9 months.
This combination demonstrated activity in HNSCC, with fewer responses in SGC. Toxicities were higher than reported with Keytruda® alone.
- Zolinza® is approved for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)
- Keytruda® is approved for across a broad range of cancers, such as Renal cell cancer, Lung cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Gastric cancer and many others.
Contact us to find out what is the best treatment for YOU
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039